Ultragenyx Pharmaceutical Inc’s recently made public that its Chief Financial Officer Horn Howard unloaded Company’s shares for reported $72114.0 on Mar 06 ’25. In the deal valued at $40.40 per share,1,785 shares were sold. As a result of this transaction, Horn Howard now holds 106,169 shares worth roughly $3.81 million.
Then, Kassberg Thomas Richard sold 6,028 shares, generating $253,779 in total proceeds. Upon selling the shares at $42.10, the CBO & EVP now owns 265,238 shares.
Before that, Parschauer Karah Herdman sold 12,846 shares. Ultragenyx Pharmaceutical Inc shares valued at $540,817 were divested by the EVP and Chief Legal Officer at a price of $42.10 per share. As a result of the transaction, Parschauer Karah Herdman now holds 75,287 shares, worth roughly $2.7 million.
Goldman upgraded its Ultragenyx Pharmaceutical Inc [RARE] rating to a Buy from a a Neutral in a research note published on June 06, 2024; the price target was increased to $67 from $56. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Wells Fargo began covering RARE with “an Overweight” recommendation on December 08, 2023.
Price Performance Review of RARE
On Tuesday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock jump 1.44% to $35.91. Over the last five days, the stock has gained 2.84%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -14.64% since the year began. Nevertheless, the stocks have fallen -17.22% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $29.59 was recorded on 04/09/25. SMA at 50 days reached $38.74, while 200 days put it at $46.61.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 35.33, which if violated will result in even more drops to 34.75. On the upside, there is a resistance level at 36.41. A further resistance level may holdings at 36.91. The Relative Strength Index (RSI) on the 14-day chart is 48.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.41, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.39%. Stochastics %K at 80.37% indicates the stock is a selling.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2025-03-31, dropping by 62198.0 shares to a total of 4.53 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 4.59 million shares. There was a decline of -1.37%, which implies that there is a negative sentiment for the stock.
